These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33268844)

  • 1. COVID-19, host response treatment, and the need for political leadership.
    Fedson DS
    J Public Health Policy; 2021 Mar; 42(1):6-14. PubMed ID: 33268844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What treating Ebola means for pandemic influenza.
    Fedson DS
    J Public Health Policy; 2018 Aug; 39(3):268-282. PubMed ID: 30013135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinician-initiated research on treating the host response to pandemic influenza.
    Fedson DS
    Hum Vaccin Immunother; 2018 Mar; 14(3):790-795. PubMed ID: 29058516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
    Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.
    Rogosnitzky M; Berkowitz E; Jadad AR
    JMIR Public Health Surveill; 2020 May; 6(2):e19199. PubMed ID: 32374264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
    Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Pandemic. New challenge for hospital pharmacy services.
    Bermejo-Vicedo T; Queralt Gorgas M
    Farm Hosp; 2020 Jun; 44(7):3-4. PubMed ID: 32533660
    [No Abstract]   [Full Text] [Related]  

  • 12. An overview of potential therapeutic agents to treat COVID-19.
    Dong X; Tian Z; Shen C; Zhao C
    Biosci Trends; 2020 Nov; 14(5):318-327. PubMed ID: 33100290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.
    Bartoli A; Gabrielli F; Alicandro T; Nascimbeni F; Andreone P
    Intern Emerg Med; 2021 Mar; 16(2):281-308. PubMed ID: 33398609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
    Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
    J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.
    Chitalia VC; Munawar AH
    J Transl Med; 2020 Oct; 18(1):390. PubMed ID: 33059719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.